ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)
China · Delayed Price · Currency is CNY 21.44
-0.16 (-0.74%)
Jun 10, 2026, 3:00 PM CST
ChengDu ShengNuo Biotec Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 795.32 | 735.37 | 451.08 | 431.32 | 386.88 | 369.3 |
Other Revenue | 6.09 | 6.09 | 4.99 | 3.7 | 8.84 | 17.23 |
| 801.4 | 741.46 | 456.07 | 435.02 | 395.72 | 386.53 | |
Revenue Growth (YoY) | 49.42% | 62.58% | 4.84% | 9.93% | 2.38% | 2.05% |
Cost of Revenue | 345.98 | 328.87 | 202.84 | 163.38 | 142.39 | 110.67 |
Gross Profit | 455.42 | 412.59 | 253.23 | 271.64 | 253.33 | 275.86 |
Selling, General & Admin | 148.73 | 137.66 | 126.53 | 161.01 | 157.82 | 190.73 |
Research & Development | 60.92 | 54.91 | 49.17 | 29.05 | 23.29 | 13.75 |
Other Operating Expenses | 5.3 | 4.29 | 3.11 | 1.24 | 4.72 | 4.8 |
Operating Expenses | 222.35 | 201.96 | 187.17 | 194.37 | 188.29 | 210.14 |
Operating Income | 233.07 | 210.63 | 66.06 | 77.27 | 65.04 | 65.71 |
Interest Expense | -18.31 | -15.14 | -11.8 | -9.08 | -3.24 | -0.17 |
Interest & Investment Income | 3.21 | 3.46 | 3.75 | 3.92 | 4.57 | 4.2 |
Currency Exchange Gain (Loss) | -0.76 | -0.76 | 0.78 | 0.5 | 3 | -0.67 |
Other Non Operating Income (Expenses) | -1.15 | -2.56 | -0.21 | -0.29 | -1.55 | -0.5 |
EBT Excluding Unusual Items | 216.06 | 195.62 | 58.57 | 72.33 | 67.82 | 68.58 |
Gain (Loss) on Sale of Investments | 0.38 | 0.25 | 0.16 | -1.42 | - | - |
Gain (Loss) on Sale of Assets | -0.06 | 0.01 | - | -0.91 | -0.39 | -4.89 |
Asset Writedown | -1.57 | -1.54 | -0.59 | - | - | - |
Other Unusual Items | -5.21 | -5.21 | 3.37 | 10.12 | 4.93 | 6.8 |
Pretax Income | 209.59 | 189.13 | 61.51 | 80.12 | 72.36 | 70.49 |
Income Tax Expense | 32.42 | 31.24 | 11.67 | 9.8 | 7.88 | 9.24 |
Earnings From Continuing Operations | 177.17 | 157.89 | 49.84 | 70.32 | 64.48 | 61.25 |
Minority Interest in Earnings | -0 | 0.03 | 0.19 | 0.01 | - | - |
Net Income | 177.17 | 157.92 | 50.02 | 70.34 | 64.48 | 61.25 |
Net Income to Common | 177.17 | 157.92 | 50.02 | 70.34 | 64.48 | 61.25 |
Net Income Growth | 119.62% | 215.70% | -28.88% | 9.08% | 5.28% | 2.09% |
Shares Outstanding (Basic) | 221 | 221 | 219 | 219 | 218 | 198 |
Shares Outstanding (Diluted) | 221 | 221 | 219 | 222 | 218 | 198 |
Shares Change (YoY) | 0.66% | 1.03% | -1.60% | 2.04% | 10.22% | 20.09% |
EPS (Basic) | 0.80 | 0.71 | 0.23 | 0.32 | 0.30 | 0.31 |
EPS (Diluted) | 0.80 | 0.71 | 0.23 | 0.32 | 0.30 | 0.31 |
EPS Growth | 118.17% | 212.47% | -27.73% | 6.89% | -4.49% | -14.98% |
Free Cash Flow | 15.28 | 32.68 | -222.2 | -193.2 | -40.23 | -11.81 |
Free Cash Flow Per Share | 0.07 | 0.15 | -1.01 | -0.87 | -0.18 | -0.06 |
Dividend Per Share | 0.251 | 0.251 | 0.071 | 0.102 | 0.091 | 0.109 |
Dividend Growth | 251.96% | 251.96% | -30.00% | 11.96% | -16.65% | - |
Gross Margin | 56.83% | 55.65% | 55.52% | 62.44% | 64.02% | 71.37% |
Operating Margin | 29.08% | 28.41% | 14.49% | 17.76% | 16.44% | 17.00% |
Profit Margin | 22.11% | 21.30% | 10.97% | 16.17% | 16.30% | 15.85% |
Free Cash Flow Margin | 1.91% | 4.41% | -48.72% | -44.41% | -10.17% | -3.06% |
EBITDA | 294.31 | 266.53 | 100.62 | 104.92 | 88.77 | 83.65 |
EBITDA Margin | 36.73% | 35.95% | 22.06% | 24.12% | 22.43% | 21.64% |
D&A For EBITDA | 61.24 | 55.9 | 34.56 | 27.65 | 23.72 | 17.94 |
EBIT | 233.07 | 210.63 | 66.06 | 77.27 | 65.04 | 65.71 |
EBIT Margin | 29.08% | 28.41% | 14.49% | 17.76% | 16.44% | 17.00% |
Effective Tax Rate | 15.47% | 16.52% | 18.98% | 12.23% | 10.89% | 13.10% |
Revenue as Reported | 801.4 | 741.46 | 456.07 | 435.02 | 395.72 | 386.53 |
Advertising Expenses | - | 2.69 | 1.92 | 0.5 | 0.09 | 0.18 |